Skip to main content
SpringerLink
Log in

Mitogen-Activated Protein Kinases as Therapeutic Targets for Rheumatoid Arthritis

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which imbalances in pro- and anti-inflammatory cytokines promote the induction of autoimmunity, inflammation and joint destruction. Methotrexate, the standard disease-modifying anti-rheumatic drug (DMARD), has shown a gradual loss of efficacy in a significant proportion of patients, probably due to the onset of drug resistance, and thus it was hoped that the development of biologics would revolutionise RA management. Even though biologics have improved the therapy of patients refractive to DMARDs, they require parenteral administration and may leave patients open to serious infection and cancer. Therefore, attention has also been focused on inhibitors of mitogen-activated protein kinases (MAPKs), signalling enzymes that play key roles in pathogenic cytokine production, and their downstream effector pathways, in order to create safe and effective oral drugs. This article therefore provides an overview of the structure and function of MAPKs and their role in the pathogenesis of RA as context to describing the advances in the development of specific, druggable MAPK inhibitors. Their potential as therapies in the management of RA is also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.

    Article  PubMed  CAS  Google Scholar 

  2. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429–42.

    Article  PubMed  CAS  Google Scholar 

  3. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11):3537–45.

    Article  PubMed  CAS  Google Scholar 

  4. Cai L, Yin JP, Starovasnik MA, Hogue DA, Hillan KJ, Mort JS, et al. Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine. 2001;16(1):10–21.

    Article  PubMed  CAS  Google Scholar 

  5. Muller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005;1(2):102–10.

    Article  PubMed  CAS  Google Scholar 

  6. Zhou FH, Foster BK, Zhou XF, Cowin AJ, Xian CJ. TNF-alpha mediates p38 MAP kinase activation and negatively regulates bone formation at the injured growth plate in rats. J Bone Miner Res. 2006;21(7):1075–88.

    Article  PubMed  CAS  Google Scholar 

  7. Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol. 1984;11(6):760–3.

    PubMed  CAS  Google Scholar 

  8. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312(13):818–22.

    Article  PubMed  CAS  Google Scholar 

  9. Williams HJ, Willkens RF, Samuelson CO Jr, Alarcon GS, Guttadauria M, Yarboro C, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthr Rheum. 1985;28(7):721–30.

    Article  CAS  Google Scholar 

  10. Morgan C, Lunt M, Brightwell H, Bradburn P, Fallow W, Lay M, et al. Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis. 2003;62(1):15–9.

    Article  PubMed  CAS  Google Scholar 

  11. Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther. 2012;91(1):30–43.

    Article  PubMed  CAS  Google Scholar 

  12. Hot A, Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis. 2011;70(5):727–32.

    Article  PubMed  CAS  Google Scholar 

  13. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003;2(9):717–26.

    Article  PubMed  CAS  Google Scholar 

  14. Cohen S. Small molecular therapies for rheumatoid arthritis: where do we stand? Expert Opin Investig Drugs. 2012;21(1):23–31.

    Article  PubMed  CAS  Google Scholar 

  15. Liu JO. The yins of T cell activation. Sci STKE. 2005;4(265):re1.

    Google Scholar 

  16. Harnett MM, Katz E, Ford CA. Differential signalling during B-cell maturation. Immunol Lett. 2005;98(1):33–44.

    Article  PubMed  CAS  Google Scholar 

  17. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467–76.

    Article  PubMed  CAS  Google Scholar 

  18. Goodridge HS, Harnett W, Liew FY, Harnett MM. Differential regulation of interleukin-12 p40 and p35 induction via Erk mitogen-activated protein kinase-dependent and -independent mechanisms and the implications for bioactive IL-12 and IL-23 responses. Immunology. 2003;109(3):415–25.

    Article  PubMed  CAS  Google Scholar 

  19. Feng GJ, Goodridge HS, Harnett MM, Wei XQ, Nikolaev AV, Higson AP, et al. Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J Immunol. 1999;163(12):6403–12.

    PubMed  CAS  Google Scholar 

  20. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372(6508):739–46.

    Article  PubMed  CAS  Google Scholar 

  21. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol. 2002;20:55–72.

    Article  PubMed  CAS  Google Scholar 

  22. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22(2):153–83.

    Article  PubMed  CAS  Google Scholar 

  23. Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell. 1997;90(5):859–69.

    Article  PubMed  CAS  Google Scholar 

  24. Turjanski AG, Vaque JP, Gutkind JS. MAP kinases and the control of nuclear events. Oncogene. 2007;26(22):3240–53.

    Article  PubMed  CAS  Google Scholar 

  25. Biondi RM, Nebreda AR. Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem J. 2003;372(Pt 1):1–13.

    Article  PubMed  CAS  Google Scholar 

  26. Tanoue T, Nishida E. Molecular recognitions in the MAP kinase cascades. Cell Signal. 2003;15(5):455–62.

    Article  PubMed  CAS  Google Scholar 

  27. Akella R, Moon TM, Goldsmith EJ. Unique MAP Kinase binding sites. Biochim Biophys Acta. 2008;1784(1):48–55.

    Article  PubMed  CAS  Google Scholar 

  28. Powers JC, Asgian JL, Ekici OD, James KE. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev. 2002;102(12):4639–750.

    Article  PubMed  CAS  Google Scholar 

  29. Morrison DK, Davis RJ. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol. 2003;19:91–118.

    Article  PubMed  CAS  Google Scholar 

  30. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007;26(22):3100–12.

    Article  PubMed  CAS  Google Scholar 

  31. Hibi M, Lin A, Smeal T, Minden A, Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 1993;7(11):2135–48.

    Article  PubMed  CAS  Google Scholar 

  32. Ortega-Perez I, Cano E, Were F, Villar M, Vazquez J, Redondo JM. c-Jun N-terminal kinase (JNK) positively regulates NFATc2 transactivation through phosphorylation within the N-terminal regulatory domain. J Biol Chem. 2005;280(21):20867–78.

    Article  PubMed  CAS  Google Scholar 

  33. Cavigelli M, Dolfi F, Claret FX, Karin M. Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J. 1995;14(23):5957–64.

    PubMed  CAS  Google Scholar 

  34. van Dam H, Wilhelm D, Herr I, Steffen A, Herrlich P, Angel P. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J. 1995;14(8):1798–811.

    PubMed  Google Scholar 

  35. Treisman R. Journey to the surface of the cell: Fos regulation and the SRE. EMBO J. 1995;14(20):4905–13.

    PubMed  CAS  Google Scholar 

  36. Fuchs SY, Adler V, Pincus MR, Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA. 1998;95(18):10541–6.

    Article  PubMed  CAS  Google Scholar 

  37. Lu G, Kang YJ, Han J, Herschman HR, Stefani E, Wang Y. TAB-1 modulates intracellular localization of p38 MAP kinase and downstream signaling. J Biol Chem. 2006;281(9):6087–95.

    Article  PubMed  CAS  Google Scholar 

  38. Saxena M, Mustelin T. Extracellular signals and scores of phosphatases: all roads lead to MAP kinase. Semin Immunol. 2000;12(4):387–96.

    Article  PubMed  CAS  Google Scholar 

  39. Zhou B, Wang ZX, Zhao Y, Brautigan DL, Zhang ZY. The specificity of extracellular signal-regulated kinase 2 dephosphorylation by protein phosphatases. J Biol Chem. 2002;277(35):31818–25.

    Article  PubMed  CAS  Google Scholar 

  40. Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 2000;14(1):6–16.

    PubMed  CAS  Google Scholar 

  41. Masuda K, Shima H, Watanabe M, Kikuchi K. MKP-7, a novel mitogen-activated protein kinase phosphatase, functions as a shuttle protein. J Biol Chem. 2001;276(42):39002–11.

    Article  PubMed  CAS  Google Scholar 

  42. Karlsson M, Mathers J, Dickinson RJ, Mandl M, Keyse SM. Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal. J Biol Chem. 2004;279(40):41882–91.

    Article  PubMed  CAS  Google Scholar 

  43. Jeffrey KL, Brummer T, Rolph MS, Liu SM, Callejas NA, Grumont RJ, et al. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol. 2006;7(3):274–83.

    Article  PubMed  CAS  Google Scholar 

  44. Fransen J, van Riel PL. Outcome measures in inflammatory rheumatic diseases. Arthr Res Ther. 2009;11(5):244.

    Article  Google Scholar 

  45. Nah SS, Won HJ, Ha E, Kang I, Cho HY, Hur SJ, et al. Epidermal growth factor increases prostaglandin E2 production via ERK1/2 MAPK and NF-kappaB pathway in fibroblast like synoviocytes from patients with rheumatoid arthritis. Rheumatol Int. 2010;30(4):443–9.

    Article  PubMed  CAS  Google Scholar 

  46. Yoo JK, Kwon H, Khil LY, Zhang L, Jun HS, Yoon JW. IL-18 induces monocyte chemotactic protein-1 production in macrophages through the phosphatidylinositol 3-kinase/Akt and MEK/ERK1/2 pathways. J Immunol. 2005;175(12):8280–6.

    PubMed  CAS  Google Scholar 

  47. Kim YG, Lee CK, Kim SH, Cho WS, Mun SH, Yoo B. Interleukin-32gamma enhances the production of IL-6 and IL-8 in fibroblast-like synoviocytes via Erk1/2 activation. J Clin Immunol. 2010;30(2):260–7.

    Article  PubMed  CAS  Google Scholar 

  48. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthr Rheum. 2000;43(11):2501–12.

    Article  CAS  Google Scholar 

  49. Geppert TD, Whitehurst CE, Thompson P, Beutler B. Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway. Mol Med. 1994;1(1):93–103.

    PubMed  CAS  Google Scholar 

  50. Barchowsky A, Frleta D, Vincenti MP. Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine. 2000;12(10):1469–79.

    Article  PubMed  CAS  Google Scholar 

  51. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001;108(1):73–81.

    PubMed  CAS  Google Scholar 

  52. Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, et al. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthr Rheum. 2003;48(6):1582–93.

    Article  CAS  Google Scholar 

  53. Liacini A, Sylvester J, Li WQ, Huang W, Dehnade F, Ahmad M, et al. Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res. 2003;288(1):208–17.

    Article  PubMed  CAS  Google Scholar 

  54. Thiel MJ, Schaefer CJ, Lesch ME, Mobley JL, Dudley DT, Tecle H, et al. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. Arthr Rheum. 2007;56(10):3347–57.

    Article  CAS  Google Scholar 

  55. Singh K, Deshpande P, Pryshchep S, Colmegna I, Liarski V, Weyand CM, et al. ERK-dependent T cell receptor threshold calibration in rheumatoid arthritis. J Immunol. 2009;183(12):8258–67.

    Article  PubMed  CAS  Google Scholar 

  56. Lindstrom TM, Robinson WH. A multitude of kinases: which are the best targets in treating rheumatoid arthritis? Rheum Dis Clin North Am. 2010;36(2):367–83.

    Article  PubMed  Google Scholar 

  57. Ohori M, Kinoshita T, Okubo M, Sato K, Yamazaki A, Arakawa H, et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun. 2005;336(1):357–63.

    Article  PubMed  CAS  Google Scholar 

  58. Ohori M. ERK inhibitors as a potential new therapy for rheumatoid arthritis. Drug News Perspect. 2008;21(5):245–50.

    Article  PubMed  CAS  Google Scholar 

  59. Ohori M, Takeuchi M, Maruki R, Nakajima H, Miyake H. FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice. Naunyn Schmiedebergs Arch Pharmacol. 2007;374(4):311–6.

    Article  PubMed  CAS  Google Scholar 

  60. Das S, Cho J, Lambertz I, Kelliher MA, Eliopoulos AG, Du K, et al. Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J Biol Chem. 2005;280(25):23748–57.

    Article  PubMed  CAS  Google Scholar 

  61. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, et al. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell. 2000;103(7):1071–83.

    Article  PubMed  CAS  Google Scholar 

  62. Hall JP, Kurdi Y, Hsu S, Cuozzo J, Liu J, Telliez JB, et al. Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem. 2007;282(46):33295–304.

    Article  PubMed  CAS  Google Scholar 

  63. Green N, Hu Y, Janz K, Li HQ, Kaila N, Guler S, et al. Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles. J Med Chem. 2007;50(19):4728–45.

    Article  PubMed  CAS  Google Scholar 

  64. Liacini A, Sylvester J, Li WQ, Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol. 2002;21(3):251–62.

    Article  PubMed  CAS  Google Scholar 

  65. Sundarrajan M, Boyle DL, Chabaud-Riou M, Hammaker D, Firestein GS. Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK. Arthr Rheum. 2003;48(9):2450–60.

    Article  CAS  Google Scholar 

  66. Inoue T, Hammaker D, Boyle DL, Firestein GS. Regulation of JNK by MKK-7 in fibroblast-like synoviocytes. Arthr Rheum. 2006;54(7):2127–35.

    Article  CAS  Google Scholar 

  67. Lee SI, Boyle DL, Berdeja A, Firestein GS. Regulation of inflammatory arthritis by the upstream kinase mitogen activated protein kinase kinase 7 in the c-Jun N-terminal kinase pathway. Arthr Res Ther. 2012;14(1):R38.

    Article  CAS  Google Scholar 

  68. Maroney AC, Finn JP, Bozyczko-Coyne D, O’Kane TM, Neff NT, Tolkovsky AM, et al. CEP-1347 (KT7515), an inhibitor of JNK activation, rescues sympathetic neurons and neuronally differentiated PC12 cells from death evoked by three distinct insults. J Neurochem. 1999;73(5):1901–12.

    PubMed  CAS  Google Scholar 

  69. Maroney AC, Finn JP, Connors TJ, Durkin JT, Angeles T, Gessner G, et al. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem. 2001;276(27):25302–8.

    Article  PubMed  CAS  Google Scholar 

  70. Cui J, Zhang M, Zhang YQ, Xu ZH. JNK pathway: diseases and therapeutic potential. Acta Pharmacol Sin. 2007;28(5):601–8.

    Article  PubMed  CAS  Google Scholar 

  71. Wang W, Ma C, Mao Z, Li M. JNK inhibition as a potential strategy in treating Parkinson’s disease. Drug News Perspect. 2004;17(10):646–54.

    Article  PubMed  CAS  Google Scholar 

  72. Bennett BL, Sasaki DT, Murray BW, O’Leary EC, Sakata ST, Xu W, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA. 2001;98(24):13681–6.

    Article  PubMed  CAS  Google Scholar 

  73. Ruckle T, Biamonte M, Grippi-Vallotton T, Arkinstall S, Cambet Y, Camps M, et al. Design, synthesis, and biological activity of novel, potent, and selective (benzoylaminomethyl)thiophene sulfonamide inhibitors of c-Jun-N-terminal kinase. J Med Chem. 2004;47(27):6921–34.

    Article  PubMed  CAS  Google Scholar 

  74. Gaillard P, Jeanclaude-Etter I, Ardissone V, Arkinstall S, Cambet Y, Camps M, et al. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J Med Chem. 2005;48(14):4596–607.

    Article  PubMed  CAS  Google Scholar 

  75. Denninger K, Rasmussen S, Larsen JM, Orskov C, Seier Poulsen S, Sorensen P, et al. JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis. Am J Pathol. 2011;179(4):1884–93.

    Article  PubMed  CAS  Google Scholar 

  76. Koller M, Hayer S, Redlich K, Ricci R, David JP, Steiner G, et al. JNK1 is not essential for TNF-mediated joint disease. Arthr Res Ther. 2005;7(1):R166–73.

    Article  CAS  Google Scholar 

  77. Gee E, Milkiewicz M, Haas TL. p38 MAPK activity is stimulated by vascular endothelial growth factor receptor 2 activation and is essential for shear stress-induced angiogenesis. J Cell Physiol. 2010;222(1):120–6.

    Article  PubMed  CAS  Google Scholar 

  78. Rousseau D, Cannella D, Boulaire J, Fitzgerald P, Fotedar A, Fotedar R. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway. Oncogene. 1999;18(30):4313–25.

    Article  PubMed  CAS  Google Scholar 

  79. Duch A, de Nadal E, Posas F. The p38 and Hog1 SAPKs control cell cycle progression in response to environmental stresses. FEBS Lett. 2012;586(18):2925–31.

    Article  PubMed  CAS  Google Scholar 

  80. Joaquin M, Gubern A, Gonzalez-Nunez D, Josue Ruiz E, Ferreiro I, de Nadal E, et al. The p57 CDKi integrates stress signals into cell-cycle progression to promote cell survival upon stress. EMBO J. 2012;31(13):2952–64.

    Article  PubMed  CAS  Google Scholar 

  81. Yoshizuka N, Chen RM, Xu Z, Liao R, Hong L, Hu WY, et al. A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis. Mol Cell Biol. 2012;32(3):606–18.

    Article  PubMed  CAS  Google Scholar 

  82. Lee JC, Young PR. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms. J Leukoc Biol. 1996;59(2):152–7.

    PubMed  CAS  Google Scholar 

  83. Tokuda H, Kanno Y, Ishisaki A, Takenaka M, Harada A, Kozawa O. Interleukin (IL)-17 enhances tumor necrosis factor-alpha-stimulated IL-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. J Cell Biochem. 2004;91(5):1053–61.

    Article  PubMed  CAS  Google Scholar 

  84. Westra J, Limburg PC, de Boer P, van Rijswijk MH. Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts. Ann Rheum Dis. 2004;63(11):1453–9.

    Article  PubMed  CAS  Google Scholar 

  85. Campbell J, Ciesielski CJ, Hunt AE, Horwood NJ, Beech JT, Hayes LA, et al. A novel mechanism for TNF-alpha regulation by p38 MAPK: involvement of NF-kappa B with implications for therapy in rheumatoid arthritis. J Immunol. 2004;173(11):6928–37.

    PubMed  CAS  Google Scholar 

  86. Young P, McDonnell P, Dunnington D, Hand A, Laydon J, Lee J. Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein level. Agents Actions. 1993;39 Spec No:C67–9.

    Google Scholar 

  87. Baldassare JJ, Bi Y, Bellone CJ. The role of p38 mitogen-activated protein kinase in IL-1 beta transcription. J Immunol. 1999;162(9):5367–73.

    PubMed  CAS  Google Scholar 

  88. Chae HJ, Chae SW, Chin HY, Bang BG, Cho SB, Han KS, et al. The p38 mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor in osteoblasts. Bone. 2001;28(1):45–53.

    Article  PubMed  CAS  Google Scholar 

  89. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005;115(2):282–90.

    PubMed  CAS  Google Scholar 

  90. Rossa C, Ehmann K, Liu M, Patil C, Kirkwood KL. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells. J Interferon Cytokine Res. 2006;26(10):719–29.

    Article  PubMed  CAS  Google Scholar 

  91. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990;145(10):3297–303.

    PubMed  CAS  Google Scholar 

  92. Thouverey C, Caverzasio J. The p38alpha MAPK positively regulates osteoblast function and postnatal bone acquisition. Cell Mol Life Sci. 2012;69(18):3115–25.

    Article  PubMed  CAS  Google Scholar 

  93. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem. 2000;275(40):31155–61.

    Article  PubMed  CAS  Google Scholar 

  94. McLay LM, Halley F, Souness JE, McKenna J, Benning V, Birrell M, et al. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg Med Chem. 2001;9(2):537–54.

    Article  PubMed  CAS  Google Scholar 

  95. Mbalaviele G, Anderson G, Jones A, De Ciechi P, Settle S, Mnich S, et al. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J Pharmacol Exp Ther. 2006;317(3):1044–53.

    Article  PubMed  CAS  Google Scholar 

  96. Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, et al. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther. 2006;318(1):132–41.

    Article  PubMed  CAS  Google Scholar 

  97. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthr Rheum. 2003;48(9):2670–81.

    Article  CAS  Google Scholar 

  98. Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthr Rheum. 2000;43(1):175–83.

    Article  CAS  Google Scholar 

  99. Korb A, Tohidast-Akrad M, Cetin E, Axmann R, Smolen J, Schett G. Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis. Arthr Rheum. 2006;54(9):2745–56.

    Article  CAS  Google Scholar 

  100. Fijen JW, Zijlstra JG, De Boer P, Spanjersberg R, Tervaert JW, Van Der Werf TS, et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol. 2001;124(1):16–20.

    Article  PubMed  CAS  Google Scholar 

  101. Parasrampuria DA, de Boer P, Desai-Krieger D, Chow AT, Jones CR. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study. J Clin Pharmacol. 2003;43(4):406–13.

    Article  PubMed  CAS  Google Scholar 

  102. Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011;38(5):846–54.

    Article  PubMed  CAS  Google Scholar 

  103. Haddad JJ. VX-745. Vertex pharmaceuticals. Curr Opin Investig Drugs. 2001;2(8):1070–6.

    PubMed  CAS  Google Scholar 

  104. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthr Rheum. 2009;60(5):1232–41.

    Article  Google Scholar 

  105. Goldstein DM, Kuglstatter A, Lou Y, Soth MJ. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem. 2010;53(6):2345–53.

    Article  PubMed  CAS  Google Scholar 

  106. Schreiber S, Feagan B, D’Haens G, Colombel JF, Geboes K, Yurcov M, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(3):325–34.

    Article  PubMed  CAS  Google Scholar 

  107. Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, et al. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. J Pharmacol Exp Ther. 2008;327(3):610–9.

    Article  PubMed  CAS  Google Scholar 

  108. Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthr Rheum. 2009;60(2):335–44.

    Article  CAS  Google Scholar 

  109. Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem. 2005;12(25):2979–94.

    Article  PubMed  CAS  Google Scholar 

  110. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther. 2002;93(2–3):79–98.

    Article  PubMed  CAS  Google Scholar 

  111. Fischer S, Koeberle SC, Laufer SA. p38alpha mitogen-activated protein kinase inhibitors, a patent review (2005–2011). Expert Opin Ther Pat. 2011;21(12):1843–66.

    Article  PubMed  CAS  Google Scholar 

  112. Angell RM, Angell TD, Bamborough P, Bamford MJ, Chung CW, Cockerill SG, et al. Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett. 2008;18(15):4433–7.

    Article  PubMed  CAS  Google Scholar 

  113. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 1996;279(3):1453–61.

    PubMed  CAS  Google Scholar 

  114. Borsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem. 1998;273(44):28766–72.

    Article  PubMed  CAS  Google Scholar 

  115. Goldstein DM, Gabriel T. Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem. 2005;5(10):1017–29.

    Article  PubMed  CAS  Google Scholar 

  116. Pettus LH, Wurz RP, Xu S, Herberich B, Henkle B, Liu Q, et al. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase. J Med Chem. 2010;53(7):2973–85.

    Article  PubMed  CAS  Google Scholar 

  117. Nikas SN, Drosos AA. SCIO-469 Scios Inc. Curr Opin Investig Drugs. 2004;5(11):1205–12.

    PubMed  CAS  Google Scholar 

  118. Mavunkel BJ, Chakravarty S, Perumattam JJ, Luedtke GR, Liang X, Lim D, et al. Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue. Bioorg Med Chem Lett. 2003;13(18):3087–90.

    Article  PubMed  CAS  Google Scholar 

  119. Genovese MC. Inhibition of p38: has the fat lady sung? Arthr Rheum. 2009;60(2):317–20.

    Article  Google Scholar 

  120. Schieven GL. The p38alpha kinase plays a central role in inflammation. Curr Top Med Chem. 2009;9(11):1038–48.

    Article  PubMed  CAS  Google Scholar 

  121. Tong SE, Daniels SE, Black P, Chang S, Protter A, Desjardins PJ. Novel p38alpha mitogen-activated protein kinase inhibitor shows analgesic efficacy in acute postsurgical dental pain. J Clin Pharmacol. 2012;52(5):717–28.

    Article  PubMed  CAS  Google Scholar 

  122. Svensson CI, Marsala M, Westerlund A, Calcutt NA, Campana WM, Freshwater JD, et al. Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J Neurochem. 2003;86(6):1534–44.

    Article  PubMed  CAS  Google Scholar 

  123. Ji RR, Suter MR. p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain. 2007;3:33.

    Article  PubMed  CAS  Google Scholar 

  124. Weisman MH. Newly diagnosed rheumatoid arthritis. Ann Rheum Dis. 2002;61(4):287–9.

    Article  PubMed  CAS  Google Scholar 

  125. Karcher SC, Laufer SA. Successful structure-based design of recent p38 MAP kinase inhibitors. Curr Top Med Chem. 2009;9(7):655–76.

    Article  PubMed  CAS  Google Scholar 

  126. Vertex moves to re-allocate resources from VX-745 in p38 MAP kinase program to accelerate development of second generation drug candidates VX-702 and VX-850 (media release). 24 Sep 2012 (online). http://www.prnewswire.com/news-releases/vertex-moves-to-re-allocate-resources-from-vx-745-in-p38-map-kinase-program-to-accelerate-development-of-second-generation-drug-candidates-vx-702-and-vx-850-72104487.html. Accessed 11 Jan 2013.

  127. Vertext pharmaceuticals reports third quarter 2001 financial results (media release). 24 Oct 2001 (online). http://investors.vrtx.com/releasedetail.cfm?releaseid=62799. Accessed 11 Jan 2013.

  128. Vertext pharmaceuticals initiates phase II clinical study in rheumatoid arthritis with investigational oral p38 MAP kinase inhibitor VX-702 (media release). 10 June 2005. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=233067. Accessed 11 Jan 2013.

  129. Isoquinoline inhibitors of p38: EPO patent EP1414455 http://patent.ipexl.com/EP/EP1414455.html. Accessed 11 Jan 2013.

  130. Trejo A, Arzeno H, Browner M, Chanda S, Cheng S, Comer DD, et al. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase. J Med Chem. 2003;46(22):4702–13.

    Article  PubMed  CAS  Google Scholar 

  131. Alten RE, Zerbini C, Jeka S, Irazoque F, Khatib F, Emery P, et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis. 2010;69(2):364–7.

    Article  PubMed  CAS  Google Scholar 

  132. Aston NM, Bamborough P, Buckton JB, Edwards CD, Holmes DS, Jones KL, et al. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression. J Med Chem. 2009;52(20):6257–69.

    Article  PubMed  CAS  Google Scholar 

  133. Ostenfeld T, Krishen A, Lai RY, Bullman J, Baines AJ, Green J, Anand P, Kelly M. Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study. Eur J Pain. 2012. doi:10.1002/j.1532-2149.2012.00256.x.

  134. GlaxoSmithKline. Result summaries: losmapimod. http://www.gsk-clinicalstudyregister.com/result_comp_list.jsp?phase=All&studyType=All&population=All&marketing=No&compound=losmapimod. Accessed 11 Jan 2013.

  135. Kim C, Cheng CY, Saldanha SA, Taylor SS. PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. Cell. 2007;130(6):1032–43.

    Article  PubMed  CAS  Google Scholar 

  136. Kim C, Sano Y, Todorova K, Carlson BA, Arpa L, Celada A, et al. The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol. 2008;9(9):1019–27.

    Article  PubMed  CAS  Google Scholar 

  137. Cheung PC, Campbell DG, Nebreda AR, Cohen P. Feedback control of the protein kinase TAK1 by SAPK2a/p38alpha. EMBO J. 2003;22(21):5793–805.

    Article  PubMed  CAS  Google Scholar 

  138. Opar A. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat Rev Drug Discov. 2010;9(4):257–8.

    Article  PubMed  CAS  Google Scholar 

  139. Koeberle SC, Romir J, Fischer S, Koeberle A, Schattel V, Albrecht W, et al. Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nat Chem Biol. 2012;8(2):141–3.

    Article  CAS  Google Scholar 

  140. Hammaker D, Firestein GS. “Go upstream, young man”: lessons learned from the p38 saga. Ann Rheum Dis. 2010;69(Suppl. 1):i77–82.

    Article  PubMed  CAS  Google Scholar 

  141. Bonilla-Hernan MG, Miranda-Carus ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxford). 2011;50(9):1542–50.

    Article  CAS  Google Scholar 

  142. Schieven GL, Zhang RF, Pitt S, Shen DR, Cao J, Sack J, et al. BMS-582949 is a dual action p38 kinase inhibitor well suited to avoid resistance mechanisms that increase p38 activation in cells. Arthr Rheum. 2010;62(10 Suppl.):S629–30.

    Google Scholar 

  143. Genovese MC, Gao L, Yin J, Smith S, Weinblatt ME, Smolen JS, et al. Proof of concept study for a potent p38 MAPK dual action inhibitor BMS-582949 in subjects with RA receiving concomitant methotrexate. Arthr Rheum. 2010;62(10 Suppl.):S469–70.

    Google Scholar 

  144. Gaestel M, Kotlyarov A, Kracht M. Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov. 2009;8(6):480–99.

    Article  PubMed  CAS  Google Scholar 

  145. Guma M, Hammaker D, Topolewski K, Corr M, Boyle DL, Karin M, et al. Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases MKK-3 or MKKk-6. Arthr Rheum. 2012;64(9):2887–95.

    Article  CAS  Google Scholar 

  146. Hammaker D, Boyle DL, Firestein GS. Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis. Rheumatology (Oxford). 2012;51(4):610–8.

    Article  CAS  Google Scholar 

  147. Engstrom W, Ward A, Moorwood K. The role of scaffold proteins in JNK signalling. Cell Prolif. 2010;43(1):56–66.

    Article  PubMed  CAS  Google Scholar 

  148. Gallagher TF, Seibel GL, Kassis S, Laydon JT, Blumenthal MJ, Lee JC, et al. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem. 1997;5(1):49–64.

    Article  PubMed  CAS  Google Scholar 

  149. Liverton NJ, Butcher JW, Claiborne CF, Claremon DA, Libby BE, Nguyen KT, et al. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J Med Chem. 1999;42(12):2180–90.

    Article  PubMed  CAS  Google Scholar 

  150. Koeberle SC, Fischer S, Schollmeyer D, Schattel V, Grutter C, Rauh D, et al. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase. J Med Chem. 2012;55(12):5868–77.

    Article  PubMed  CAS  Google Scholar 

  151. Liu C, Lin J, Wrobleski ST, Lin S, Hynes J, Wu H, et al. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][ 1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38alpha MAP kinase inhibitor for the treatment of inflammatory diseases. J Med Chem. 2010;53(18):6629–39.

    Article  PubMed  CAS  Google Scholar 

  152. Bode JG, Ehlting C, Haussinger D. The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell Signal. 2012;24(6):1185–94.

    Article  PubMed  CAS  Google Scholar 

  153. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537–49.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Both authors planned, drafted and revised the manuscript in collaboration. They thank the UK Medical Research Council for their support and declare no conflict of interest.

Author information

Authors and Affiliations

  1. Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, MVLS, University of Glasgow, Glasgow, G12 8TA, UK

    Verica Paunovic & Margaret M. Harnett

Authors
  1. Verica Paunovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margaret M. Harnett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Margaret M. Harnett.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paunovic, V., Harnett, M.M. Mitogen-Activated Protein Kinases as Therapeutic Targets for Rheumatoid Arthritis. Drugs 73, 101–115 (2013). https://doi.org/10.1007/s40265-013-0014-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-013-0014-6

Keywords

Search

Navigation